# Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

> **NCT02092324** · PHASE2 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 51 (actual)

## Conditions studied

- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Chronic Neutrophilic Leukemia

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Ruxolitinib Phosphate

## Key facts

- **NCT ID:** NCT02092324
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-08
- **Primary completion:** 2019-11-22
- **Final completion:** 2020-01-24
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2020-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02092324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02092324, "Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02092324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*